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ABSTRACT
Introduction: Most patient safety research has
focused on specialist-care settings where there is an
appreciation of the frequency and causes of medical
errors, and the resulting burden of adverse events.
There have, however, been few large-scale robust
studies that have investigated the extent and severity of
avoidable harm in primary care. To address this, we
will conduct a 12-month retrospective cross-sectional
study involving case note review of primary care
patients.
Methods and analysis: We will conduct electronic
searches of general practice (GP) clinical computer
systems to identify patients with avoidable significant
harm. Up to 16 general practices from 3 areas of
England (East Midlands, London and the North West)
will be recruited based on practice size, to obtain a
sample of around 100 000 patients. Our investigations
will include an ‘enhanced sample’ of patients with the
highest risk of avoidable significant harm. We will
estimate the incidence of avoidable significant harm
and express this as ‘per 100 000 patients per year’.
Univariate and multivariate analysis will be conducted
to identify the factors associated with avoidable
significant harm.
Ethics/Dissemination: The decision regarding
participation by general practices in the study is entirely
voluntary; the consent to participate may be withdrawn
at any time. We will not seek individual patient consent
for the retrospective case note review, but if patients
respond to publicity about the project and say they do
not wish their records to be included, we will follow
these instructions. We will produce a report for the
Department of Health’s Policy Research Programme and
several high-quality peer-reviewed publications in
scientific journals. The study has been granted a
favourable opinion by the East Midlands Nottingham 2
Research Ethics Committee (reference 15/EM/0411) and
Confidentiality Advisory Group approval for access to
medical records without consent under section 251 of
the NHS Act 2006 (reference 15/CAG/0182).
INTRODUCTION
Background/rationale
Most patient safety research has focused on
specialist-care settings where there is now
considerable appreciation of the frequency
and causes of medical errors, and the result-
ing burden of adverse events.1–4
Epidemiological studies have shown that 3.2–
16.6% of all hospital patients experience an
error,3 5–10 and many of these result in sub-
stantial avoidable patient morbidity and con-
siderable costs to health systems.
Unfortunately, the pace of patient safety
research in primary care has in comparison
with secondary care settings been slow,11 and
only recently has the World Health
Organization (WHO) focused on safer
primary care.12
Members of our team recently completed
a WHO-commissioned systematic review13 to
determine the frequency, burden and
Strengths and limitations of this study
▪ Having a random sample of practices stratified
by list size will reduce bias.
▪ The study will take place in England, which
limits generalisability to other countries.
▪ We may miss some patients with avoidable sig-
nificant harm, although we will be able to esti-
mate how frequently this occurs.
▪ Bias may be introduced if more than a small
minority of patients objects to a review of their
records.
▪ Training and ongoing feedback will help ensure
that the general practices involved in data collec-
tion adhere to consistent methods for classifying
patients.
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preventability of patient safety incidents in primary care,
including 9 systematic reviews and 100 primary studies.
Their review highlighted that there have been few
large-scale robust studies of the seriousness and avoid-
ability of harm in primary care. Based on existing
studies, errors occur in around 2–3% of primary care
encounters, and around 1 in 25 of these errors results in
serious harm that has a substantial impact on patients’
well-being. An exception, that has informed the sample
size calculations for this study, is an investigation of over
96 000 primary care patient encounters from Spain
which showed that around 67 per 100 000 consultations
(0.067%) were associated with serious avoidable harm.14
Even though the UK has been an exemplar of high-
quality primary healthcare,15 it is important to develop
an understanding of the frequency and causes of avoid-
able harm in this setting to reduce the risks. The
current study has been designed to address this serious
gap in the literature. Once we have a better understand-
ing of the epidemiology of avoidable signiﬁcant harm in
primary care, we will have the necessary evidence to
design and evaluate interventions that will reduce the
burden of avoidable harm.
We will use retrospective case note review, which has
been used to good effect in hospital settings to estimate
the incidence of avoidable harm1 3 7 and deaths.16 We
use the term ‘harm’ to refer to ‘an outcome that nega-
tively affects a patient’s health or quality of life’.17 This is
sometimes also referred to as a ‘healthcare adverse
event’.18 In our study, we will concentrate on the most
‘signiﬁcant’ harms such as those causing loss of function
of a body organ and/or hospital admission.
In keeping with previous studies, we will focus our
investigations on an ‘enhanced sample’ of patients with
the highest risk of avoidable signiﬁcant harm,1 7 in
order to make most efﬁcient use of the time of reviewers
involved in data collection. We will also use a well-
established scale for assessing the avoidability of
harm.14 16 Our deﬁnitions of signiﬁcant harm and avoid-
ability are shown in box 1.
Objectives
The objectives of the study are to:
1. Estimate the incidence of avoidable signiﬁcant harm
in primary care in England,
2. Quantify, describe and classify the patient safety inci-
dents that result in avoidable signiﬁcant harm and
their severity,
3. Identify ameliorable factors that, if addressed, could
help reduce the incidence of avoidable signiﬁcant
harm in primary care, and
4. Based on the ﬁndings of the research (ie, objectives
1–3 above):
- Advise on the development of new measures at
national and local levels, aimed at ensuring that the
NHS Outcomes Framework includes primary care in
relation to risks of avoidable harm.
- Advise on the extent to which future assess-
ments of avoidable harm in primary care could be
made more efﬁcient through interrogation of elec-
tronic health records.
- Advise on interventions that might help reduce
the incidence of avoidable harm.
METHODS
Study design
We will undertake a retrospective cross-sectional study
involving case note review of a cohort of primary care
patients that attended the GP clinic within a 12-month
window prior to the beginning of the study. We will
conduct electronic searches of clinical computer systems
in general practices (for 12 months from the start of the
retrospective cohort) to identify patients at increased
risk of avoidable signiﬁcant harm.
Setting
We plan to recruit general practices from three geo-
graphically dispersed areas of England (East Midlands,
London and the North West).
Eligibility of GPs for entering the study
Inclusion criteria
General practices will be eligible to participate if:
▸ They provide written informed consent.
▸ They deliver NHS services.
▸ They have electronic health records (this is the case
for almost all general practices in England) and use
one of the three main GP computer systems in
England: EMIS Web (EMIS Health 2016), SystmOne
(The Phoenix Partnership 2016) or INPS Vision (In
Practice Systems, 2016).
▸ Their electronic health records can reliably identify
patients who have been admitted to secondary care.
Exclusion criteria
General practices will be excluded from the study if they
are involved in a major reorganisation (such as a merger
with another practice) since this would make it difﬁcult
to identify the practice list size for the retrospective case
note review.
Box 1
Definitions of significant harm and avoidability
Significant harm: A patient outcome is symptomatic, which
required more intensive intervention than might otherwise have
been required (eg, additional operative procedure) and resulted in
an escalation of care (eg, hospital admission), or death. This
caused a loss of function of at least one bodily organ, which may
have been a temporary or permanent loss of its function.
Avoidable: An error of omission (failing to do the right thing) or
commission (doing something wrong) in healthcare management
that reflects a failure to follow acceptable practice at an individual
or system level
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Recruitment of general practices and data collectors
We will use a stratiﬁed random sampling technique to
approach the general practices. We plan to recruit up to 16
general practices stratiﬁed (in quartiles) by list size. Up to 18
independent general practices will be recruited and trained
to undertake data collection in the general practices.
We will email and/or write to general practices (via
the practice manager and general practices within the
practices) inviting participation. We will use a range of
approaches to encourage participation, including prior
publicity about the study, engaging local opinion leaders
and providing reassurance about data conﬁdentiality. We
will encourage retention of the general practices in the
study by ensuring that the data collection procedures
are not disruptive to the workings of the practice, and
that the GP reviewers involved in data collection build
good working relationships with the practices. Practices
will be reimbursed for their time, and GP reviewers will
be paid for their work on the project.
Participants
Inclusion criteria
All patients in these practices will be considered poten-
tially eligible for inclusion in the study, although we will
identify an ‘enhanced sample’ in each practice of
patients who are likely to have higher than the average
risk of avoidable signiﬁcant harm (see section below on
sampling for more details).
Exclusion criteria
Patients will be excluded if they have a computer code
in their clinical records, indicating that they do not wish
to be included in research studies. Patients will also be
excluded if (as a result of publicity about the project)
they state that they do not wish for their records to be
included in the retrospective case note review.
Sampling of patient records
Our approach to sampling of patient records will be a
three-stage process:
Stage 1: Identify total population of the practices at the
start of the retrospective cohort
Stage 2: Identify patients at increased risk of avoidable
harm (the ‘enhanced sample’)
Stage 3: Identify those from stage 2 who have experi-
enced a signiﬁcant new heath problem during the
12-month retrospective review period
The population for stage 1 will be those patients regis-
tered with the general practices at the start of the retro-
spective cohort (which will be 12 months before the
date that sampling begins in each practice). We antici-
pate a total population of around 100 000 (based on 16
practices with a median list size of 6250). Figure 1 shows
the stages in our study.
In order to identify patients at increased risk of avoid-
able harm (stage 2), we will draw on suggestions made
by the commissioners of the research (the Department
of Health), the literature on avoidable harm in primary
care (see references in the bullet list below) and our
own experience of inductively analysing reports of harm
associated with primary care in the National Reporting
and Learning System.19 Search strategies will be devel-
oped and tested for each of the aforementioned
medical record systems. Searches of records at each
practice (for 12 months from the start of the retrospect-
ive cohort) will identify patients who may be at increased
risk of having experienced avoidable signiﬁcant harm.
We plan to include the following categories of patient:
▸ Died16
▸ Admitted to hospital or a mental health facility20
▸ Certiﬁed unﬁt for work (long-term sick leave)
▸ Resident in a care home21
▸ Undergone an invasive procedure in GP such as a
minor operation or joint injection22
▸ Major polypharmacy (10 or more repeat
medications)23 24
▸ Four or more major signiﬁcant morbidities
In addition, we will include patients identiﬁed by the
participating general practices as having experienced
avoidable harm (eg, from signiﬁcant event audits25).
Based on pilot work, and running an algorithm inclusive
of these categories in EMIS in an urban GP surgery with a
practice list size of 13 000, we anticipate that this ‘at risk’
enhanced sample could constitute around 10% of the
average general practice population, for example, 10 000
patients in total across all of the participating practices.
Figure 1 Flow chart showing how patient records are
selected.
Bell BG, et al. BMJ Open 2017;7:e013786. doi:10.1136/bmjopen-2016-013786 3
Open Access
In each of the participating general practices, a
spreadsheet will be generated listing those patients at
increased risk of avoidable harm. The spreadsheet will
contain patient demographic information (name, date
of birth and NHS number) and a unique ‘Patient Study
Number’ will be generated for each patient. The spread-
sheet will be password-protected and stored on the GP
practice’s clinical system (with a back-up ﬁle elsewhere
on the system). A hard copy will be printed out and
used by the GP reviewers to identify patients in subse-
quent stages of the sampling. This hard copy will remain
in the practice at all times.
The next stage of sampling (stage 3) will identify
patients with signiﬁcant health problems (irrespective of
whether they are avoidable or not). It will involve one of
the GP reviewers screening the electronic health records
of patients to identify any new signiﬁcant health pro-
blems, including accidents, experienced by patients over
the 12 months of the study, irrespective of the cause
(this will include all deaths). Our pilot work has shown
that this is the most efﬁcient way of identifying patients
with potentially avoidable harm; ∼25% of the ‘Stage 2
sample’ are likely to be highlighted, that is, 2500
patients in total across all of the practices. The research
team will provide the GP reviewers with comprehensive
guidance on the health problems we want to screen for;
this will include all new major physical and psychiatric
morbidities, and accidents. Detailed record review will
be performed on this ﬁnal sample of patients to identify
the extent to which failures in primary healthcare con-
tribute to any of these signiﬁcant health problems.
For a subsequent sensitivity analysis in which poten-
tially avoidable harm that might have been ‘missed’ as a
result of the above sampling process is accounted for in
the estimation of the incidence of avoidable signiﬁcant
harm, the GP reviewers will screen the following:
1. 2.5% random sample of ‘Stage 1’ patients not
included in the ‘Stage 2’ sample (2250 patients in
total across all of the practices);
2. 10% random sample of the ‘Stage 2’ patients will be
screened again by a second GP reviewer (around
1000 patients in total across all of the practices);
3. For any patients identiﬁed (by these two processes)
as potentially having avoidable signiﬁcant harm, the
GP reviewers will undertake retrospective records
review (as described below).
Undertaking the retrospective record reviews
In each practice, two of the GP reviewers will independ-
ently undertake a retrospective record review to identify
cases of avoidable signiﬁcant harm. Where potentially
avoidable signiﬁcant harm is detected, the retrospective
case note reviews will go back to the root of the
problem, for example, the failure to act on ‘red ﬂag’
symptoms 5 years before a delayed diagnosis of inoper-
able cancer. To help in the identiﬁcation of cases, the
GP reviewers will be encouraged to identify ‘triggers’
indicating potential errors,26 for example, signiﬁcantly
out-of-range laboratory test results. In addition, the GP
reviewers will have access to other primary healthcare
professionals on our study team if they need advice on
the avoidability of harm in primary care outside general
practice. In keeping with a number of previous studies,
the GP reviewers will judge the ‘avoidability’ of harm on
a six-point scale (see table 1).14 16
Data collection
For those cases of harm considered to be at least ‘pos-
sibly avoidable’, one of the GP reviewers will record par-
tially anonymised data onto a case report form to be
retained in a study site ﬁle in the participating general
practices. The case report forms will be stored in a
secure location in the general practice, for example,
locked cabinet or locked ofﬁce and separate to the hard
copy of the spreadsheet.
The GP reviewers will also record pseudonymised data
relating to their retrospective case note reviews onto a
specially designed data collection system on a tablet
computer for synchronous transfer to a secure database
server at Cardiff University (no information will be
retained on the tablet computer itself). All devices will
be encrypted, remotely managed and password-
protected. The pseudonymised data (based on the
spreadsheet generated for stage 2 of the sampling
process) will consist of the unique ‘Patient Study
Number’, age and sex of each patient, but no informa-
tion that could allow the patient to be identiﬁed from
outside the practice.
For stage 3, the GP reviewers will record whether they
judge the patients to have experienced a signiﬁcant health
problem during the 12-month retrospective data collec-
tion period. Then, as part of the retrospective case note
review, the reviewers will record their judgements of the
avoidability of the health problems detected. For those
patients judged to have experienced avoidable signiﬁ-
cant harm, the GP reviewers will record the nature of
the avoidable harm using the comprehensive patient
safety classiﬁcation system developed in the PISA study.27
The multiaxial PISA classiﬁcation system will permit
Table 1 Six-point avoidability scale
Rating Category Description
1 Totally
unavoidable
Virtually no evidence of
avoidability
2 Unavoidable Slight to modest evidence of
avoidability
3 Possibly
avoidable
Possibly avoidable, <50–50,
but close call
4 Probably
avoidable
Probably avoidable, more than
50–50, but close call
5 Probably
avoidable
Strong evidence of avoidability
6 Totally
avoidable
Virtually certain evidence of
avoidability
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reviewers to choose codes to describe the type of safety
incident (eg, administration, medication), identify con-
tributory factors (eg, patient comorbidity, staff work
load) and report patient harm severity as described by
the WHO International Classiﬁcation for Patient
Safety.27 The recursive model for incident analysis27 28
will be applied using a series of rules to enable consist-
ent coding between reviewers, an applied example is
provided in ﬁgure 2.
Ensuring consistency of judgements regarding avoidable
significant harm
A subgroup of the study team will meet regularly during
the data collection period and will review all of the infor-
mation provided by the GP reviewers. They will provide
feedback to the reviewers on the quality of their reports,
and consistency of their coding, in order to help ensure
improvements where necessary. They will also discuss the
judgements of the reviewers concerning the presence of
avoidable signiﬁcant harm and the classiﬁcation of this.
To ensure consistency, the study team will make the ﬁnal
judgement in terms of the classiﬁcation of avoidable sig-
niﬁcant harm, particularly if the paired GP reviewers dis-
agree on their classiﬁcation. If further information is
needed in order for the subgroup to make an informed
judgement, we will ask one of the GP reviewers to go
back and obtain this. Also, if the perspective of a particu-
lar member of the primary healthcare team is required
to help make a judgement, the subgroup will discuss the
case with a relevant member of the wider study team.
Bias
Sampling of practices and patients
To reduce bias, we will recruit a stratiﬁed random
sample of practices in the East Midlands, London and
Greater Manchester. All patients within a practice will be
potentially eligible for inclusion, although bias may be
introduced if patients with more serious conditions
object to a review of their records. As noted above, to
assess the possibility that patients with avoidable signiﬁ-
cant harm will not be included in the enhanced sample,
a 2.5% random sample of ‘Stage 1’ patients not included
in the ‘Stage 2’ sample will be reviewed. To assess the
possibility that the GP reviewers may ‘miss’ patients with
signiﬁcant harm when reviewing the stage 2 sample, a
10% random sample of these patients will be screened
by a second GP reviewer.
Training of reviewers
The main issue is the extent to which the GP reviewers
involved in the retrospective case note review adhere to
consistent methods for identifying and classifying
patients with avoidable signiﬁcant harm. To reduce
reviewer bias, e-learning and face-to-face training will be
provided to GP reviewers on human factors in health-
care, principles of patient safety incident analysis and
patient safety incident coding using the PISA classiﬁca-
tion system. All identiﬁed cases of avoidable signiﬁcant
harm will be double-coded by GPs.
The ﬁndings of each pair of GPs will be compared to
determine the extent to which the GP reviewers agree
Figure 2 The recursive model for incident analysis. Illustrative case: a man aged 67 years presents to see a locum GP, with a
6-week history of fatigue, which he only mentions while leaving at the end of a consultation where four other problems were dealt
with, including hypertension, psoriasis, knee pain and a medication review. As fatigue was presented right at the very end, the
locum documents this and arranges for some blood tests and asks the patient to return in 2 weeks for review. No systems review
or examination is documented. The patient has his bloods taken. The full blood count sample is reported as ‘not labelled’ and no
results are given; the urea and electrolytes and liver function tests were all within the reference ranges. When another GP in the
practice looks at the results—she marks them as normal. The patient calls for the results and to make an appointment, but as the
bloods are reported as normal, he decides not to make one. Six months later, he presents back to his usual GP who notices he
is very pale and has lost weight. Systems review identifies an 8-month history of loose motions, and examination reveals a large
mass in his left iliac fossa. Haemoglobin is 70 g/L and ferritin is 3 µg/L. Further investigation reveals inoperable adenocarcinoma
of the sigmoid colon.
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on the identiﬁcation and classiﬁcation of avoidable sig-
niﬁcant harm. Disagreements will be monitored in real
time and discussed in regular teleconference calls with a
view to ensuring correct interpretation of codes and
their deﬁnitions. These calls will also allow GPs to bring
difﬁcult cases for peer discussion, and to agree to any
developments in classiﬁcation (ie, new codes, changes in
deﬁnitions) and/or coding rules.
Study size
On the basis of our pilot study, our suggested sample
size of 100 000 patients is the largest we can manage
within the funding available while also conducting the
study to the highest standards of rigour. The aim of our
calculations is to identify the precision for which a popu-
lation incidence of avoidable harm can be estimated for
a given sample size of 100 000 patients. The estimates
are shown in table 2 for a range of incidences of avoid-
able signiﬁcant harm (the ﬁgure of 80/100 000 patients
per year is highlighted as we think this is at the lower
boundary of the likely incidence).14
ANALYSES
Descriptive analysis
We will describe the demographics of the study popula-
tion (in terms of age, sex, ethnicity and deprivation) and
compare this informally with: (1) data for England from
the Ofﬁce of National Statistics and English Indices of
Deprivation; (2) any practices that were approached but
did not agree to take part. We will also describe patient
demographics (the age distribution and sex) of those
with potentially avoidable harm and for the subsamples
identiﬁed in stages 2–3. In addition, we will describe the
characteristics of the GPs, including GP training status
and workload (based on consultation rates).
We will estimate the incidence of avoidable signiﬁcant
harm and express this as ‘per 100 000 patients per year’
accompanied by 95% conﬁdence intervals (CIs). We will
do this initially on the ‘assumption’ that our sampling
process has identiﬁed all the avoidable signiﬁcant harms
in the overall population. We will also do a sensitivity
analysis to take account of the proportion of harms that
might have been missed by our sampling processes. We
will estimate the incidence of:
▸ Signiﬁcant harm judged at least possibly avoidable
▸ Signiﬁcant harm judged at least probably avoidable
(this will be our principal outcome)
Patterns of avoidable signiﬁcant harm will be sum-
marised, focusing particularly on the types of safety
event, such as administration of medication, the setting
(eg, general practice, community pharmacy, community
nursing, etc), the types of staff involved and outcomes
including severity of harm.
Statistical analysis
Univariate analysis, followed by multivariable analysis
adjusting for confounders, will be conducted to identify
the factors (relating to patients and general practices)
associated with avoidable signiﬁcant harm, for example,
risk of avoidable harm could be higher in practices with
the greatest workload.
We will assess inter-rater reliability of judgements
made by paired GP reviewers using the Kappa statistic
(with 95% CI). These assessments will be undertaken on
the following judgements:
▸ Identiﬁcation of patients with signiﬁcant new health
problems (signiﬁcant harm) from a 10% random
sample of the ‘Stage 2’ sample.
▸ Identiﬁcation of patients with signiﬁcant harm
judged at least possibly avoidable.
▸ Identiﬁcation of patients with signiﬁcant harm
judged at least probably unavoidable.
ETHICS
The decision regarding participation by general
practices in the study is entirely voluntary. The investiga-
tor (who will be a member of the study team) will
explain the details of the study and provide a practice
information sheet, ensuring that the practice team have
sufﬁcient time to consider participating or not. The
investigator or their nominee shall emphasise to general
practices that consent regarding study participation may
be withdrawn at any time without having to give a reason
for this and without penalty. The investigator (usually
one of the GP reviewers) will inform the senior repre-
sentative of the general practice of any relevant informa-
tion that becomes available during the course of the
study (such as serious safety incidents), and will discuss
with them whether they wish to continue with the study.
We do not plan to seek individual patient consent for
the retrospective case note review. If (as a result of local
publicity about the project) patients state that they do
not wish their records to be included in the retrospect-
ive case note review, the GP reviewers involved in the
data collection will respect these requests and not
include the patients. Patients will be able to make their
request for their records not to be included in the study
Table 2 Degree of precision of estimates of the incidence
of avoidable significant harm
Estimated
incidence of
avoidable
significant harm
(per 100 000
patients per year)
Precision
(width of
95% CI)
95% CIs based on
a sample size of
100 000 patients
20 9 11 to 29
40 12 28 to 52
80 18 62 to 98
100 20 82 to 120
200 28 172 to 228
Bold values are the lower bound of the likely incidence.
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by contacting their practice and a withdrawal form will
be completed. To allow patients the opportunity to
dissent, consented practices will be asked to display the
study information 6 weeks before the data collection
period begins. Patients will be excluded if they have a
computer code in their clinical records, indicating that
they do not wish to be included in research studies.
The PPI representatives will be members of the
project management group, which will convene at least
once monthly, and they will actively contribute to
ongoing discussions about the conduct of the study.
They will also contribute to at least one of the early
meetings with GPs who will be involved in data collec-
tion so that they can provide their views on the operatio-
nalisation of deﬁnitions of avoidable signiﬁcant harm in
the study.
DISSEMINATION
We will meet with relevant colleagues within NHS
England towards the end of the project to appraise
them of the key ﬁndings. We will speciﬁcally discuss
potential new measures for the NHS Outcomes
Framework, and the conduct of future assessments of
the scale and nature of avoidable harm in primary care.
We will explore methods of further dissemination with
the Primary Care Patient Safety Expert Group (NHS
England) including holding an event and running webi-
nars. Similarly, we will engage with the network of NHS
England Patient Safety Collaboratives and advise on
interventions aimed at reducing the incidence of avoid-
able signiﬁcant harm in primary care.
We expect to produce the following outputs from our
research:
▸ The production of robust generalisable information
on the frequency, nature and seriousness of avoidable
signiﬁcant harm in primary care.
▸ A report for the Department of Health’s Policy
Research Programme.
▸ Several high-quality peer-reviewed publications in sci-
entiﬁc journals, which we will report using STROBE
and RECORD guidelines.
▸ Presentations at meetings and conferences for service
users, healthcare professionals, policymakers and
academics.
▸ A range of materials for healthcare professionals to
help them with strategies for analysing and reducing
the incidence and impact of avoidable signiﬁcant
harm in their contexts (these will be performed after
the project has been completed, and without add-
itional charge to the Department of Health).
▸ Materials for service users to help them to recognise
the potential for avoidable harm in primary health-
care, and how they might work with healthcare pro-
fessionals to avoid these harms, for example, by
voicing concerns.
▸ The PPI representatives will run patient stakeholder
events to provide emerging ﬁndings to service users
in order to gauge likely responses to the publication
of our report.
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